Maxbon 150 mg (Tablet)
1 tablet kit: ৳ 510.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibandronic acid |
| Company | Square pharmaceuticals plc |
Title and Categories
- Maxbon Tablet
- Pharmacology
- Medicine
- Bisphosphonate preparations
Indications
- Treatment of osteoporosis in women (specially postmenopausal)
- Prevention of osteoporosis in women (specially postmenopausal)
- Prevention and treatment of osteoporosis in men
Pharmacological Action
- Inhibition of bone resorption
- Prevents experimentally induced bone destruction
- Highly potent inhibitor of osteoclastic activity
- Reduces bone resorption with no direct effect on bone formation
Dosage and Administration
- Recommended dose of one 150 mg film-coated tablet once a month
- Should be taken 60 minutes before the first food or drink of the day
- Tablet should be swallowed whole with a full glass of plain water
Interaction
- Interference with the absorption of calcium supplements and antacids
- Absence of interaction potential with tamoxifen or hormone replacement therapy
- Increase in bioavailability with ranitidine
- Does not inhibit major human hepatic P450 isoenzymes
- No induction of the hepatic cytochrome P450 system in rats
Contraindications
- Known hypersensitivity to ibandronic acid or excipients
- Uncorrected hypocalcemia
- Abnormalities of the esophagus delaying esophageal emptying
- Inability to stand or sit upright for at least 60 minutes
Side Effects
- Dyspepsia
- Nausea
- Diarrhea
- Abdominal pain
- Muscle aches
- Headaches
- Dizziness
Pregnancy and Lactation
- Not to be used during pregnancy
- No clinical experience with pregnant women
- Not to be used during lactation
- Concentration in breast milk corresponding to about 5% of plasma concentration after 24 hours
Precautions and Warnings
- Effective treatment of hypocalcemia and other disturbances of bone and mineral metabolism before starting therapy
- Caution in patients with active upper gastrointestinal problems
- Esophageal adverse experiences, including ulcers and erosions
- No increased risk observed in clinical trials for gastric and duodenal ulcers
- Risk of osteonecrosis of the jaw, especially in cancer patients undergoing dental procedures
- No established safety and efficacy in patients less than 18 years old
Use in Special Populations
- No dosage adjustment necessary for patients with mild or moderate renal impairment
- No dosage adjustment necessary for patients with hepatic impairment
- No dosage adjustment necessary for elderly patients
- Safety and efficacy not established in patients less than 18 years old
Overdose Effects
- No specific information available on treatment
- Oral overdosage may result in upper gastrointestinal adverse events
- Milk or antacids should be given to bind Maxbon
- Vomiting should not be induced
Storage Conditions
- Keep below 30°C temperature
- Away from light and moisture
- Keep out of the reach of children